Managed Access Programs for LNP023, Iptacopan

NCT05222412 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-12-05

No results posted yet for this study

Summary

The purpose of this registration form is to list all Managed Access Programs (MAPs) related to LNP023, Iptacopan

Conditions

  • C3 Glomerulopathy (C3G)
  • Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

DRUG

Iptacopan

Patients receive Iptacopan

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05222412 on ClinicalTrials.gov